Pathway candidateNCBI-verifiedprotein-coding

CYP1A2

cytochrome P450 family 1 subfamily A member 2

NCBI Gene: 1544 Ensembl GeneCards UniProt: P05177

Pathway candidate — not linked to PFS or PSSD by any record here

CYP1A2 is in the library because it belongs to the drug metabolism family. No study, report or commentary in the corpus names it, so a variant in CYP1A2 is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 15 (drug metabolism (phase i)). Encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Cytochrome P450 1A2
Function (excerpt): A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis. May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid.
Pathway: Cofactor metabolism; retinol metabolism. Steroid metabolism; cholesterol metabolism. Lipid metabolism; arachidonate metabolism.
Subcellular location: Endoplasmic reticulum membrane; Microsome membrane.
Tissue specificity: Liver.

Source: UniProtKB/Swiss-Prot P05177, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Phase I enzymes determine exposure to finasteride, SSRIs, and other implicated drugs; variation here shapes the likelihood and persistence of adverse effects.

Written for the whole drug metabolism family, not for CYP1A2 specifically.

Mentioned in 0 corpus records

No corpus record names CYP1A2 directly yet. It is in the library because it sits in a pathway the corpus tracks (Drug metabolism).

Also in drug metabolism (phase i)

All 23 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Cytochrome P450 1A2
Function (excerpt): A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis. May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid.
Pathway: Cofactor metabolism; retinol metabolism. Steroid metabolism; cholesterol metabolism. Lipid metabolism; arachidonate metabolism.
Subcellular location: Endoplasmic reticulum membrane; Microsome membrane.
Tissue specificity: Liver.